The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori.

摘要: Backgrounds/Aims: Most of patients who are refractory to usual standard eradication therapies for H. pylori infection have rapid metabolizer genotype CYP2C19 and infected with resistant strains several antimicrobial agents. However, most sensitive amoxicillin. We tested whether dual therapy the 4 times daily dosing rabeprazole amoxicillin was effective as 3 rd rescue regimen pylori. Methodology: 49 failed in after two (1 st : proton pump inhibitor (PPI)/amoxicillin/clarithromycin 2 nd PPI/amoxicillin/metronidazole) were enrolled study. They treated 10 mg q.i.d. 500 weeks. At weeks treatment, they underwent [ 13 C]-urea breath test. When result test negative, endoscopy successful confirmed by urease Results: All completed treatment. The rate 87.8% (43/49) (95% CI=75.2%-95.4%). No undesirable severe adverse events observed during study period. Conclusions: is well tolerated 3rd